Abiopharma

BrainStorm Cell Therapeutics Inc. is a clinical-stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone
marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The
companys current primary targets are Amyotrophic Lateral Sclerosis (ALS, also known as
Lou Gehrigs disease) and Parkinsons disease (PD). These devastating diseases have no
treatment options and as such represent highly unmet medical needs. Upon completion
of BrainStorms clinical trials program and regulatory approvals, this novel therapy will
provide compelling medical and economic benefits for patients, medical practitioners,
and insurance/healthcare providers. By redirecting the inherent regenerative capacities
of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable
healthcare institutions and society at large to realize massive savings in treatment and
care costs. The Company holds rights to develop and commercialize the technology
through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel-Aviv University.

Additional info from OTC:
BrainStorm Cell Therapeutics Inc. is a clinical-stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone
marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The
companys current primary targets are Amyotrophic Lateral Sclerosis (ALS, also known as
Lou Gehrigs disease) and Parkinsons disease (PD). These devastating diseases have no
treatment options and as such represent highly unmet medical needs. Upon completion
of BrainStorms clinical trials program and regulatory approvals, this novel therapy will
provide compelling medical and economic benefits for patients, medical practitioners,
and insurance/healthcare providers. By redirecting the inherent regenerative capacities
of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable
healthcare institutions and society at large to realize massive savings in treatment and
care costs. The Company holds rights to develop and commercialize the technology
through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel-Aviv University.